Cerebral venous thrombosis and Covid 19: Literature review

Introduction: Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) was first detected in December 2019 the city of Wuhan, China, and has since taken on worldwide proportions. It is known that individuals with Coronavirus disease-19 (COVID-19) have systemic clinical manifestations. Among multisystemic effects, cerebral venous thrombosis (CVT) responsible for high mortality rates. In this sense, understanding association between CVT SARS-CoV-2 infection directly impacts disease's morbidity mortality. Methodology: Literature review PubMed Embase databases, following search terms: “COVID-19”, “SARS-CoV-2”, “Venous thromboembolism”, “Thrombosis”, “Cerebral Venous Thrombosis”, “Intracranial Sinus Thrombosis” “Cranial Thrombosis”. The selected articles were written English, which addressed various aspects COVID-19. Results discussion: are a rare complication COVID-19, an incidence 0.02 to 1% hospitalized patients. However, it can reach about 75% affected individuals. Pathophysiology seems be associated state hypercoagulability inflammatory process resulting from viral infection. Thus, recent studies show consensus early anticoagulation patients by virus, reduce these cases. differences types anticoagulation, Low Molecular Weight Heparin (LMWH), Unfractionated (UFH), Dabigatran not yet been well established, although there predilection use LMWH. Also, thrombectomy therapeutic intervention option should evaluated, due risk additional endothelial injury stent retrievers. Conclusion: Although relatively low incidence, aggravates condition increases death Because this, diagnosis evaluation options essential development management.